PDCD1 and breast carcinoma: Notably, another platinum derivative, PT-112, is a bone fide ICD inducer and indeed has been shown to synergize with PD-1 as well as PD-L1 blockers against subcutaneous TS/A mammary carcinomas developing in syngeneic immunocompetent BALB/c mice [42], suggesting that the ICD-inducing potential of platinum compounds depends on specific molecular features of the coordination complex and its cellular effects rather than on the platinum ion itself [10].